everolimus + anastrozole + letrozole + tamoxifen citrate + fulvestrant + megestrol acetate
Phase 2TerminatedDevelopment Stage
Estrogen Receptor-positive Breast Cancer
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Nov 25, 2014 → Jan 25, 2021
About everolimus + anastrozole + letrozole + tamoxifen citrate + fulvestrant + megestrol acetate
everolimus + anastrozole + letrozole + tamoxifen citrate + fulvestrant + megestrol acetate is a phase 2 stage product being developed by Novartis for Estrogen Receptor-positive Breast Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT02269670. Target conditions include Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02269670 | Phase 2 | Terminated |
Competing Products
20 competing products in Estrogen Receptor-positive Breast Cancer